陆控此前于1月27日发布建议更换核数师公告，公告提及PwC对某些交易提出关注。对此，陆控审计委 员会已委聘国际领先律所、法证会计师等进行独立调查，主要调查结果事实如下：1）公司作为唯一投 资人投资于若干信托，并通过信托购买若干资产，并非用于补偿关联实体在先前与本公司进行的交易中 蒙受的损失，而是用于赔偿若干零售投资者于投资产品的投资损失，以及向另一关联实体购置若干其他 资产。2）为实现前述交易，公司向第三方银行出售及转让若干高收益资产后转回予相关信托，从而降 低道德风险及目标资产账面值潜在的减值风险。基于上述情况，董事会目前预估，截至22年12月31日 止财政年度，公司合并资产总值预计将增加不超过0.5%，合并净利润预计不会发生实质性变化；截至 23年12月31日止财政年度，公司合并资产总值预计将减少不超过2%，合并净利润预计将减少8%至15% （即人民币0.83亿元至人民币1.55亿元）。另一项PwC函件中所提及的交易与上述任何交易均无关连。 公告同步发布公司多项改善举措，包括进一步优化董事会及管理层架构、追偿安排、委聘独立内控顾问 及设置特别委员会以提升内控等。公司亦将委任继任核数师重新审计本公司截至22 ...

Group 1 - The 2025 Aerospace Culture and Art Forum was held in Shanghai as part of the 10th "China Aerospace Day" activities, featuring discussions on the synergy between sports and aerospace spirit [2][3] - Athletes and entrepreneurs, including Li Ning and Olympic diving champion Quan Hongchan, emphasized the shared pursuit of perfection in both aerospace and sports [2][3] - Li Ning expressed pride in China's aerospace achievements, highlighting the dedication and exploration behind these accomplishments [2] Group 2 - Quan Hongchan drew parallels between diving and aerospace, likening each dive to a rocket launch aimed at achieving a perfect entry [3] - Li Ning highlighted the importance of integrating aerospace technology into sports and daily life, indicating a potential collaboration to create innovative sportswear [3][6] - The establishment of an Aerospace Technology Innovation Application Laboratory aims to apply advanced aerospace technology to professional sports equipment, promoting innovation and cultural dissemination [6] Group 3 - The "Aerospace Quick-Dry" and "Aerospace Sun Protection" technologies were showcased at the forum, demonstrating successful technology transfer from aerospace to sports apparel [6] - The "Aerospace Quick-Dry" technology utilizes design inspired by rocket launch systems to enhance moisture management in fabrics [6] - The "Aerospace Sun Protection" technology features a nano-coating inspired by spacesuits, achieving a UV protection factor (UPF) of 950 and a UV blockage rate of 99.9% [6]

Policy Developments - The National Health Commission held its first press conference in 2025 to promote the Sanming healthcare reform experience, emphasizing the importance of public hospital reform guided by public welfare [1] - The Sanming reform integrates medical services, insurance, and pharmaceuticals, establishing a new mechanism that ensures sustainability and public interest, serving as a model for national healthcare reform [1] Medical Device Approvals - Pumen Technology's subsidiary received a medical device registration certificate for an electronic bladder and renal pelvis endoscope, enhancing the company's product portfolio in clinical medical fields [2] - Xinhua Pharmaceutical obtained a drug registration certificate for pregabalin oral solution, which is included in the National Basic Medical Insurance drug list for 2024 [3] - Renfu Pharmaceutical's subsidiary received a drug registration certificate for naproxen sodium soft capsules, marking the first approval for this product in the domestic market [4] Financial Reports - Ping An Good Doctor reported a first-quarter net profit of 33.188 million yuan, with total revenue of 1.062 billion yuan, a 25.8% increase year-on-year [5] - Baiyang Pharmaceutical achieved a revenue of 8.094 billion yuan and a net profit of 692 million yuan, with a 9.17% year-on-year growth in revenue [6][7] - Heyuan Bio reported a first-quarter net loss of 59 million yuan, with a revenue decline of 11.29% [8] - Nuotai Bio's first-quarter net profit increased by 130.10% year-on-year, with revenue growth of 58.96% [9] Capital Market Activities - Changde Medical successfully completed an over 100 million yuan A+ round financing, with funds allocated for clinical trials and international market expansion [10] Industry Developments - The National Medical Insurance Administration reported that from January to March 2025, there were 95.8683 million instances of personal account mutual aid in employee medical insurance, totaling 13.198 billion yuan [11] - Boehringer Ingelheim entered a global licensing agreement with Tessellate Bio to develop oral precision therapies for cancer patients, with a total transaction value exceeding 500 million euros (approximately 573 million USD) [12] Shareholder Actions - Innovation Medical announced that a major shareholder reduced its stake by 4.7 million shares, decreasing its ownership from 7.6414% to 6.5763% [13]

"美国市场原本大约占我们业务的一半，另一半则是欧盟市场。尽管欧盟市场仍在运营，但未来充满不 确定性，因此我们非常希望有机会能够拓展内销市场。"舟山格林食品有限公司内销主管叶晓萦表 示，"让我们惊喜的是，从开始商谈到商品上架，仅用了三天时间，效率远超预期。" "我们非常重视帮助外贸企业解决困难。"朱敏介绍，从省商务厅会议到公司专题会议，再到与供应商对 接、选品、验厂，并与市场监管部门协同解决标签、准入等问题，我们仅用三天时间就完成常规需要大 概一个月的流程。目前，首批商品已配送至36家门店，下周将快速扩展至200家门店销售。 "这得益于我们第一时间成立的专班，"朱敏表示，联华超市专门成立涉及安全质量、采购、运营、法 务、财务等跨部门专项小组，简化审批流程，与政府部门建立直通渠道，实现问题即时解决。目前，42 家外贸企业正在洽谈中，2家已经入驻上架销售，预估下周7家将入驻售卖。下一步，"我们将引入更多 的优质外贸供应商，通过重点单品让消费者享受到更高品质的商品和服务。" "这个虾吃起来口感很特别，不像那种软绵绵的。相反，它吃上去很有嚼劲，而且味道非常鲜美。这和 我之前吃过的品种感觉完全不同。"正在选购的周阿姨赞不 ...

国际货币基金组织高级官员：日本经济增长和通胀的风险偏向下行。 ...

预计发行认购股份所得款项净额(扣除开支后)约为1285.83万港元，而每股认购股份的净价格约为3.93港 元。预计发行可转换票据所得款项净额(扣除开支后)约为5133万港元，而每股转换股份的净价格约为4.9 港元。公司拟以下列方式运用所得款项净额总额：最高约641.88万港元(占所得款项净额总额最高约 10%)将用作一般营运资金;及最高约5776.95万港元(占所得款项净额总额最高约90%)将用于把握日后可 能出现的潜在投资机会，探索加密货币投资及Web 3.0的机会，及/或收购比特币等数字资产。于本公告 日期，除在公开市场收购比特币外，集团并无发现任何具体的潜在投资机会或目标。 认购股份相当于经发行认购股份扩大后的股份总数的约0.81%(假设自本公告日期起及直至发行认购股份 完成日期的股份总数概无其他变动)。按初始转换价每股转换股份5港元计算，因悉数行使可转换票据附 带的转换权而将予配发及发行的转换股份合共为1047.55万股，相当于经发行认购股份及转换股份扩大 后的已发行股份总数的约2.53%(假设除发行认购股份外，自本公告日期起直至可转换票据按初始转换价 获悉数转换完成，股份总数概无其他变动)。认购价每 ...

陆控ADR美股盘后涨0.38%，该公司港交所公告宣布Yong Suk Cho（赵容奭）将继续担任CEO，Alston Zhu辞去 CFO、任命Tongzhuan Xi（席通专）为新的CFO。 陆金所控股有限公司 NYSE: LU ! 概览 对比 财务信息 謝永林先生 市场概况 > 陆金所控股有限公司 2.62 USD + 关注 +0.15 (6.07%) ↑ 今天 收盘时间: 4月23日 GMT-4 下午5:10 · 免责声明 盘后价 2.63 +0.010 (0.38%) 6 个月 YTD 1 天 5天 1 个月 1年 5年 最大 2.70 2.65 2.60 2.55 昨日 2.50 收盘价 2.47 2.45 上午10:00 下午12:00 下午2:00 下午4:00 下午6:00 下午8:00 22.71亿 开盘 2.49 52 周高点 市值 4.94 2.00 最高 2.66 市盈率 52 周低点 時得所控股 JIFAX Lufax Holding Ltd 陆金所控股有限公司 (於開曼群島註冊成立的有限公司) (股份代號：6623) (紐交所股票代碼：LU) 董事名單及其角色和職能 陆金所控股有限公 ...

IBM(IBM.N)：宏观经济环境不稳定；维持全年收入增长和自由现金流预期不变。 ...

Core Viewpoint - The head-to-head trial results of Iwosimab (PD-1/VEGF dual antibody) against the PD-1 therapy from BeiGene demonstrate significant clinical benefits, marking a milestone in the treatment of squamous non-small cell lung cancer (sq-NSCLC) [1][2][3] Group 1: Clinical Trial Results - Iwosimab combined with chemotherapy showed strong positive results compared to BeiGene's Tislelizumab combined with chemotherapy in a pivotal Phase III trial (AK112-306/HARMONi-6) for advanced sq-NSCLC [1] - The trial results indicate statistically significant benefits and major clinical advantages, which are expected to enhance treatment options for sq-NSCLC patients [2][3] - Iwosimab has previously demonstrated a doubling of median progression-free survival (mPFS) in a head-to-head trial against Merck's Keytruda (Pembrolizumab) [2] Group 2: Market Impact and Company Performance - Following the announcement of the trial results, Kangfang Biopharma's stock surged over 10%, reaching a historical high of 100 HKD per share, with a cumulative increase of over 40% in recent times [2] - The sales figures for Tislelizumab are projected to be 3.806 billion CNY in 2023 and 4.467 billion CNY in 2024, indicating its status as a leading domestic PD-1 therapy [2] Group 3: Industry Trends and Innovations - The Chinese innovative drug sector is increasingly taking the lead in lung cancer treatment, with a notable shift from "follower" to "leader" status in various therapeutic areas [6] - The latest National Medical Insurance directory includes 12 new drugs for lung cancer treatment, reflecting the growing innovation in the Chinese pharmaceutical industry [6] - The overall five-year survival rate for late-stage lung cancer patients in China has improved from 5% during the chemotherapy era to 20%-30% currently, although it still lags behind the overall cancer survival rate of 43% [6] Group 4: Future Prospects - Kangfang Biopharma is expected to release international multi-center Phase III clinical data for Iwosimab in 2025, which could lead to a submission for FDA approval if results are positive [8] - The company emphasizes the importance of head-to-head trials to establish the clinical value of new therapies against existing standards [4][5]